Figure 2.
Quantification of humoral and cellular Spike-specific immune responses
(A) Spike immunoglobulin G (IgG) antibody, sVNT, Spike-specific memory B cells (MBCs), and T cell responses were tested in five cohorts of naive vaccinated individuals: J (n = 12), J+J (n = 23), J+P (n = 9), P (n = 10), and P+P (n = 37). A naive unvaccinated cohort was used as a control (Unvac; n = 10–22). Bars denote the median value of each group. Each dot represents an individual. Significant differences in each group were analyzed by one-way ANOVA, and the adjusted p values (adjusted for multiple comparison) are shown. No significance is not shown, ∗p ≤ 0.05; ∗∗p ≤ 0.01; ∗∗∗p ≤ 0.001; ∗∗∗∗p ≤ 0.0001.
(B) Linear regression analysis between neutralizing antibody activity (top panels) or Spike-specific T cell frequency (bottom panels) and time of testing after last vaccine dose (days). Goodness of fit and p values are shown in plots.
(C) Bar graphs show the proportion of vaccinees with varying levels of Spike-IgG antibodies, neutralizing antibodies, and Spike-specific B and T cell frequencies. The type of responders (strong/moderate/none-weak) was expressed as a fraction of the number of vaccine recipients in each cohort. Type of responders were determined by percentile score calculated from all the vaccinees (n = 87–91).